CN108473550B - 具有脂肪酸取代基的egf(a)类似物 - Google Patents

具有脂肪酸取代基的egf(a)类似物 Download PDF

Info

Publication number
CN108473550B
CN108473550B CN201780006783.6A CN201780006783A CN108473550B CN 108473550 B CN108473550 B CN 108473550B CN 201780006783 A CN201780006783 A CN 201780006783A CN 108473550 B CN108473550 B CN 108473550B
Authority
CN
China
Prior art keywords
ethoxy
egf
amino
peptide
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780006783.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473550A (zh
Inventor
陈建和
J.F.刘
J.T.科德拉
B.维乔雷克
L.林德罗特
H.托格森
S.E.拉斯姆森
P.W.加里贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN108473550A publication Critical patent/CN108473550A/zh
Application granted granted Critical
Publication of CN108473550B publication Critical patent/CN108473550B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201780006783.6A 2016-01-13 2017-01-13 具有脂肪酸取代基的egf(a)类似物 Active CN108473550B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/070791 2016-01-13
CN2016070791 2016-01-13
CNPCT/CN2016/076580 2016-03-17
CN2016076580 2016-03-17
EP16195965 2016-10-27
EP16195965.5 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (2)

Publication Number Publication Date
CN108473550A CN108473550A (zh) 2018-08-31
CN108473550B true CN108473550B (zh) 2022-11-22

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780006783.6A Active CN108473550B (zh) 2016-01-13 2017-01-13 具有脂肪酸取代基的egf(a)类似物

Country Status (26)

Country Link
US (2) US10822385B2 (enExample)
EP (1) EP3402811B1 (enExample)
JP (2) JP6797926B2 (enExample)
KR (1) KR102417487B1 (enExample)
CN (1) CN108473550B (enExample)
AU (1) AU2017207862B2 (enExample)
BR (1) BR112018013820A2 (enExample)
CA (1) CA3010756A1 (enExample)
CL (1) CL2018001868A1 (enExample)
CO (1) CO2018007440A2 (enExample)
DK (1) DK3402811T3 (enExample)
ES (1) ES2916998T3 (enExample)
HR (1) HRP20220720T1 (enExample)
HU (1) HUE058647T2 (enExample)
IL (1) IL260043A (enExample)
LT (1) LT3402811T (enExample)
MX (1) MX2018008681A (enExample)
MY (1) MY195199A (enExample)
PE (1) PE20181376A1 (enExample)
PH (1) PH12018501502A1 (enExample)
PL (1) PL3402811T3 (enExample)
RS (1) RS63298B1 (enExample)
RU (1) RU2747877C2 (enExample)
SA (1) SA518391996B1 (enExample)
SI (1) SI3402811T1 (enExample)
WO (1) WO2017121850A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60224B1 (sr) 2016-01-13 2020-06-30 Gruenenthal Gmbh Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
HRP20250176T1 (hr) 2016-01-13 2025-04-11 Grünenthal GmbH Derivati 3-((hetero-)aril)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
AU2017207862B2 (en) 2016-01-13 2020-12-17 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
JP6917379B2 (ja) 2016-01-13 2021-08-11 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
AR107360A1 (es) 2016-01-13 2018-04-25 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
WO2019016306A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S BIFUNCTIONAL COMPOUNDS
CN111164098A (zh) * 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
MA53809A (fr) * 2018-10-05 2022-01-12 Novo Nordisk As Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
US11633632B2 (en) 2019-03-22 2023-04-25 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
CN114222581A (zh) 2019-08-07 2022-03-22 诺和诺德股份有限公司 包含egf(a)衍生物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
AU2020378624A1 (en) 2019-11-07 2022-04-21 Novo Nordisk A/S Solid compositions comprising a PCSK9 inhibitor and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2024527488A (ja) 2021-07-02 2024-07-25 スリーエム イノベイティブ プロパティズ カンパニー 落下防止安全装置と連動される空中リフト
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093735A (zh) * 2011-09-23 2014-10-08 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015185640A1 (en) * 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909823A2 (en) 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
MX2010011499A (es) * 2008-04-23 2010-11-12 Amgen Inc Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN103052900A (zh) * 2010-08-02 2013-04-17 日本电气株式会社 偏振器和发光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
MX2013015311A (es) * 2011-06-20 2014-03-31 Genentech Inc Polipeptidos de enlace de pcsk9 y metodos de uso.
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2794648A1 (en) * 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
SG11201500682WA (en) 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
BR112016017402A2 (pt) 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
AU2017207862B2 (en) 2016-01-13 2020-12-17 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
WO2019016306A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S BIFUNCTIONAL COMPOUNDS
CN111164098A (zh) 2017-07-19 2020-05-15 诺沃挪第克公司 Egf(a)类似物、其制品、制剂和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093735A (zh) * 2011-09-23 2014-10-08 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015185640A1 (en) * 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain;Yingnan Zhang et al.;《Journal of Molecular Biology》;20121231;全文 *
蛋白质多肽类药物的脂肪酸修饰研究进展;王玥 等;《药学进展》;20151231;全文 *

Also Published As

Publication number Publication date
AU2017207862A1 (en) 2018-07-05
JP6797926B2 (ja) 2020-12-09
RS63298B1 (sr) 2022-07-29
JP2021035989A (ja) 2021-03-04
JP2019505521A (ja) 2019-02-28
WO2017121850A1 (en) 2017-07-20
US10822385B2 (en) 2020-11-03
US20200407409A1 (en) 2020-12-31
KR102417487B1 (ko) 2022-07-06
CA3010756A1 (en) 2017-07-20
PE20181376A1 (es) 2018-09-05
AU2017207862B2 (en) 2020-12-17
PH12018501502A1 (en) 2019-03-25
CO2018007440A2 (es) 2018-09-28
SI3402811T1 (sl) 2022-06-30
US20190016768A1 (en) 2019-01-17
IL260043A (en) 2018-07-31
ES2916998T3 (es) 2022-07-06
HUE058647T2 (hu) 2022-09-28
PL3402811T3 (pl) 2022-07-11
CL2018001868A1 (es) 2018-08-31
LT3402811T (lt) 2022-06-10
MX2018008681A (es) 2018-09-17
KR20180100177A (ko) 2018-09-07
BR112018013820A2 (pt) 2018-12-11
HRP20220720T1 (hr) 2022-09-30
RU2018127882A3 (enExample) 2020-06-19
DK3402811T3 (da) 2022-06-13
MY195199A (en) 2023-01-11
RU2747877C2 (ru) 2021-05-17
SA518391996B1 (ar) 2021-07-14
EP3402811A1 (en) 2018-11-21
EP3402811B1 (en) 2022-03-30
CN108473550A (zh) 2018-08-31
RU2018127882A (ru) 2020-02-13

Similar Documents

Publication Publication Date Title
CN108473550B (zh) 具有脂肪酸取代基的egf(a)类似物
CN102791731B (zh) Glp-1类似物和衍生物
CN101005857A (zh) 多肽延长标记
US11649269B2 (en) Bifunctional compounds comprising insulin peptides and EGF(A) peptides
CN100444898C (zh) 治疗肽的清蛋白结合型衍生物
KR20170075779A (ko) Gip 효능제 화합물 및 방법
KR20060109940A (ko) 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
CN104411322B (zh) 双酰化glp‑1衍生物
JP7339236B2 (ja) 二機能性化合物
CN111164098A (zh) Egf(a)类似物、其制品、制剂和用途
KR20220097921A (ko) 인터루킨-22의 치료 유도체
KR20070108180A (ko) 구조적으로 잘 정의된 분지형 중합체와 콘쥬게이트된인슐린분비제 유도체
HK1262866B (en) Egf(a) analogues with fatty acid substituents
WO2025043696A1 (zh) 抗病毒多肽类似物
CN116970042A (zh) 抗病毒多肽类似物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment